Ralinepag vs Treprostinil (Orenitram)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Ralinepag
Developed by United Therapeutics under a licence from Arena Pharmaceuticals, Inc.
NCT03626688 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled, event-driven Phase 3 trial with 687 patients in the full analysis set (728 randomized; 41 patients from sites in China excluded), measuring time to first clinical worsening event as the primary endpoint. The peer-reviewed report in The Lancet gives a hazard ratio of 0.45 (95% CI 0.33-0.62; p<0.0001) for ralinepag versus placebo, with more discontinuations for adverse events on ralinepag (19% vs 3%).
Next expected readout: December 2026 · NCT03683186 (registry estimate)
Reported efficacy
Time from randomization to the first adjudicated protocol-defined clinical worsening event (The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years): Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. (met)
Result source: NCT03626688
Treprostinil (Orenitram)
Marketed by United Therapeutics
NCT00325403 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 349 participants enrolled and 228 included in the prespecified primary analysis. The clinical primary endpoint was met: oral treprostinil produced a statistically significant placebo-corrected improvement in six-minute walk distance at Week 12.
Reported efficacy
Six Minute Walk Distance (6MWD) (Baseline and Week 12): Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49) (met)
Result source: NCT00325403
Results for Pulmonary Arterial Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Ralinepag: 7 of 7 rows · Treprostinil (Orenitram): 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ralinepag Rows use multiple source trials | Treprostinil (Orenitram) Rows use multiple source trials |
|---|---|---|
| 6MWD - Change absolute change · m | 36.2 vs 29.4 placebo m @ 22wka,b,c,d NCT02279160 · Phase 2 · registry result, not featured evidence | 395.4 vs 372.3 placebo m @ 24wka,b,c,d NCT01560624 · Phase 3 · registry result, not featured evidence |
| 6MWD - Change absolute change · m No placebo or comparator arm | -120 m @ 221wkb,e NCT02279745 · Phase 2 · registry result, not featured evidence | 2.7 m @ 24wkf,b,e NCT02276872 · Phase 2 · registry result, not featured evidence show 2 more doses22.1 m @ 24wk NCT02276872 · Phase 2 · registry result, not featured evidence 12.8 m @ 24wk NCT02276872 · Phase 2 · registry result, not featured evidence · combination |
| Cardiac Index Change L/Min M2 absolute change · L/min No placebo or comparator arm | 0 L/minb,g NCT02279745 · Phase 2 · registry result, not featured evidence | 0.303 L/min @ 24wkf,b,g NCT02276872 · Phase 2 · registry result, not featured evidence show 2 more doses0.767 L/min @ 24wk NCT02276872 · Phase 2 · registry result, not featured evidence 0.121 L/min @ 24wk NCT02276872 · Phase 2 · registry result, not featured evidence · combination |
| Dropout rate | 44.4%h NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result15% NCT02279160 · Phase 2 · registry result, not featured evidence | 21.9%i NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more results42.1% NCT01560637 · Phase 3 · registry result, not featured evidence 76.7% NCT01027949 · Phase 3 · registry result, not featured evidence 57.2% NCT01560624 · Phase 3 · registry result, not featured evidence 12.1% NCT00325442 · Phase 3 · registry result, not featured evidence 10%Cohort 1 (Transitioning From Paren NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 2 (Transitioning From Inhal NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 3 (Add-on to Current PAH Th NCT02276872 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 15.6%h NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result— NCT02279160 · Phase 2 · registry result, not featured evidence | —i NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more results13.4% NCT01560637 · Phase 3 · registry result, not featured evidence 19.2% NCT01027949 · Phase 3 · registry result, not featured evidence — NCT01560624 · Phase 3 · registry result, not featured evidence — NCT00325442 · Phase 3 · registry result, not featured evidence 10%Cohort 1 (Transitioning From Paren NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 2 (Transitioning From Inhal NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 3 (Add-on to Current PAH Th NCT02276872 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 46.7%h NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result10% NCT02279160 · Phase 2 · registry result, not featured evidence | 17.9%i NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more results43.8% NCT01560637 · Phase 3 · registry result, not featured evidence 61.2% NCT01027949 · Phase 3 · registry result, not featured evidence 33.5% NCT01560624 · Phase 3 · registry result, not featured evidence 18.4% NCT00325442 · Phase 3 · registry result, not featured evidence 50%Cohort 1 (Transitioning From Paren NCT02276872 · Phase 2 · registry result, not featured evidence 0%Cohort 2 (Transitioning From Inhal NCT02276872 · Phase 2 · registry result, not featured evidence 33.3%Cohort 3 (Add-on to Current PAH Th NCT02276872 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | h headache 64.4% diarrhoea 37.8% pain in jaw 33.3% NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more resultheadache 77.5% (placebo 28.6%) nausea 50% (placebo 23.8%) diarrhoea 47.5% (placebo 14.3%) NCT02279160 · Phase 2 · registry result, not featured evidence | i headache 62.9% (placebo 19.5%) diarrhea 30.5% (placebo 15.6%) nausea 29.8% (placebo 18.2%) NCT00325403 · Phase 3 · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 7 more resultsheadache 69.8% diarrhoea 66.2% flushing 42.8% NCT01560637 · Phase 3 · registry result, not featured evidence headache 78.1% diarrhoea 66.2% nausea 56.5% NCT01027949 · Phase 3 · registry result, not featured evidence headache 74.9% (placebo 34.9%) diarrhoea 69.4% (placebo 28.5%) flushing 44.5% (placebo 7.8%) NCT01560624 · Phase 3 · registry result, not featured evidence headache 86.2% (placebo 36.9%) nausea 64.4% (placebo 34.1%) diarrhea 60.9% (placebo 27.3%) NCT00325442 · Phase 3 · registry result, not featured evidence headache 100% diarrhoea 75% nausea 75% NCT02276872 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 22 weeks versus 24 weeks.
- eAssessment timepoints differ: 221 weeks versus 24 weeks.
- fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- gThe assessment timepoint is not available for both results.
- hPopulation comparability has not been reviewed for these studies.
- iPopulation comparability has not been reviewed for 7 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ralinepag
Treprostinil (Orenitram)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
+ 15 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ralinepag's landscape · Treprostinil (Orenitram)'s landscape